



Quality transfusion diagnostics products.

301 South State Street, Ste S-204 | Newtown, Pennsylvania 18940 | T 888-284-1901 | F 888-694-5208 | W quotientbd.com

CONTACT:

Michael Hannan
Quotient Biodiagnostics
215-497-8820
michael.hannan@quotientbd.com

FOR IMMEDIATE RELEASE

QUOTIENT BIODIAGNOSTICS WINS 5-YEAR AWARD TO SUPPLY BLOOD BANK REAGENTS TO THE U.S. GOVERNMENT

QUOTIENT NOW AN APPROVED VENDOR FOR VETERANS AFFAIRS, INDIAN HEALTH SERVICES, AND OTHER GOVERNMENT HOSPITALS THROUGH GENERAL SERVICES AGENCY CONTRACT

NEWTOWN, PA (December 1, 2011) Quotient Biodiagnostics, Inc., dedicated to providing high quality immunohematology products to blood banks and hospitals, today announced that it has been awarded a five year contract to supply its blood bank reagents to the federal government. Through the Federal Supply Schedule, Quotient can now sell its products unencumbered to the nearly 200 Veterans Affairs, Indian Health Services, and military hospitals worldwide. The agreement includes Quotient's first 24 products in its proprietary line of manual transfusion diagnostics, and can be updated when future products are approved by the U.S. Food & Drug Administration (FDA).

"We are very excited to be an approved vendor to the U.S. Government, and look forward to being a key partner in helping military and other government hospitals to meet their tightening budget requirements over the coming years", said Michael Hannan, E.V.P., Commercial Operations, Quotient Biodiagnostics. "We see this contract as a further validation that our business philosophy of delivering high quality products with superior customer service at a good value is appreciated by our customers, whether they are a small hospital or the U.S. government."

Formed in 2009 to bring its products to the U.S. market, Quotient Biodiagnostics sells its proprietary line of antisera products under the trade names ALBAclone[®], ALBAcyte[®], ALBAcheck[®], ALBAhance[™], and ALBAlect[™]. Quotient provides innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market to help ensure safe and reliable transfusions at a reasonable cost.

Quotient Biodiagnostics' current portfolio now includes products used in ABO blood typing, namely Anti-A, Anti-B, Anti-AB, Anti-A₁; Rh typing reagents including four Anti-D products, Rh Control, Anti-E, and Anti-c; and rare anti-sera including Anti-k, Anti-M, Anti-N, Anti- Le^a, Anti-Le^b, and Anti-Lu^b – all monoclonal antibodies. Quotient also has three enhancement media products on the market including Bovine Serum Albumin 22%, PEG and LISS Additive.

In addition, Quotient launched the first of its red blood cell products, IgG sensitized cells, a surprisingly large component of a blood bank's budget.

As well, Quotient has three specialty kits in its current portfolio including the ALBAcheck[®] Competency Training Kit, which includes a collection of 20 blinded antibody samples that can be used to train or evaluate staff competency Identifying; the ALBAclone[®] Advanced Partial RhD Typing Kit, which identifies weak and partial RhD types with results comparable to molecular analysis at a fraction of the cost; Quant-Rho[®] FITC Anti-D product that quantifies Fetal Maternal Hemorrhage without the tribulations of KB staining. Finally, Quotient has several applications pending before, or soon to be submitted to, the FDA to complete its full portfolio of manual reagents of nearly 75 products.

Since announcing its expansion into the U.S. transfusion market in 2009, Quotient Biodiagnostics has made significant progress in building its customer base and product use, supported by its more than 30 years of experience in Europe and other markets, quality manufacturing and commitment to service excellence.

Those interested in learning more about Quotient Biodiagnostics and its line of products are encouraged to visit www.quotientbd.com, or call the customer service line 888-284-1901, or e-mail customer.service@quotientbd.com.

About Quotient Biodiagnostics:

Quotient Biodiagnostics Group, through its wholly owned subsidiary, Alba Bioscience, brings over 30 years of experience in the transfusion medicine market. Quotient will focus on providing innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market, helping to ensure safe and reliable blood transfusions. Quotient's goal is to develop innovative new products and technologies to serve the worldwide transfusion medicine market, build a commercial operation to market and sell the Group's blood typing and screening products, and continue as an important supplier of key raw materials and innovative new products to the Original Equipment Manufacturers market.